|
1
|
Muzny DM, Bainbridge MN, Chang K, Dinh HH,
Drummond JA, Fowler G, Kovar CL, Lewis LR, Morgan MB, Newsham IF,
et al: Cancer Genome Atlas Network: Comprehensive molecular
characterization of human colon and rectal cancer. Nature.
487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yadav L, Puri N, Rastogi V, Satpute P and
Sharma V: Tumour Angiogenesis and Angiogenic Inhibitors: A Review.
J Clin Diagn Res. 9:XE01–XE05. 2015.PubMed/NCBI
|
|
3
|
Papadimitriou K, Rolfo C, Dewaele E, Van
De Wiel M, Van den Brande J, Altintas S, Huizing M, Specenier P and
Peeters M: Incorporating anti-VEGF pathway therapy as a continuum
of care in metastatic colorectal cancer. Curr Treat Options Oncol.
16:182015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saltz LB, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tebbutt NC, Wilson K, Gebski VJ, Cummins
MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland
SP, et al: Capecitabine, bevacizumab, and mitomycin in first-line
treatment of metastatic colorectal cancer: Results of the
Australasian Gastrointestinal Trials Group Randomized Phase III MAX
Study. J Clin Oncol. 28:3191–3198. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grothey A and Ellis LM: Targeting
angiogenesis driven by vascular endothelial growth factors using
antibody-based therapies. Cancer J. 14:170–177. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shibuya M: Vascular endothelial growth
factor-dependent and -independent regulation of angiogenesis. BMB
Rep. 41:278–286. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fleck BW and McIntosh N: Pathogenesis of
retinopathy of prematurity and possible preventive strategies.
Early Hum Dev. 84:83–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Heidary G, Vanderveen D and Smith LE:
Retinopathy of prematurity: Current concepts in molecular
pathogenesis. Semin Ophthalmol. 24:77–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Karamysheva AF: Mechanisms of
angiogenesis. Biochemistry. 73:751–762. 2008.PubMed/NCBI
|
|
12
|
Kitano H: Cancer as a robust system:
Implications for anticancer therapy. Nat Rev Cancer. 4:227–235.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schrattenholz A and Soskić V: What does
systems biology mean for drug development? Curr Med Chem.
15:1520–1528. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li B, Li GG, Xiang Y and Xu LJ: VEGF
affects the expression of TGF-β in retinal neovascularization: A
preliminary study about redundancy of growth factor. Int J
Ophthalmol. 8:2391–2393. 2008.
|
|
15
|
Gacche RN and Meshram RJ: Angiogenic
factors as potential drug target: Efficacy and limitations of
anti-angiogenic therapy. Biochim Biophys Acta. 1846:161–179.
2014.PubMed/NCBI
|
|
16
|
Kerbel RS: Tumor angiogenesis. N Engl J
Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giampieri R, Scartozzi M, Del Prete M,
Fulli A, Faloppi L, Bianconi M, Maccaroni E and Cascinu S: The
‘angiogenetic ladder’, step-wise angiogenesis inhibition in
metastatic colorectal cancer. Cancer Treat Rev. 40:934–941. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mahadevan R and Lovley DR: The degree of
redundancy in metabolic genes is linked to mode of metabolism.
Biophys J. 94:1216–1220. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krakauer DC and Plotkin JB: Redundancy,
antiredundancy, and the robustness of genomes. Proc Natl Acad Sci
USA. 99:1405–1409. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Louis EJ: Evolutionary genetics: Making
the most of redundancy. Nature. 449:673–674. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saharinen P, Eklund L, Miettinen J,
Wirkkala R, Anisimov A, Winderlich M, Nottebaum A, Vestweber D,
Deutsch U, Koh GY, et al: Angiopoietins assemble distinct Tie2
signalling complexes in endothelial cell-cell and cell-matrix
contacts. Nat Cell Biol. 10:527–537. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao Y and Liu Q: Therapeutic targets of
multiple angiogenic factors for the treatment of cancer and
metastasis. Adv Cancer Res. 97:203–224. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wong ET and Brem S: Antiangiogenesis
treatment for glioblastoma multiforme: Challenges and
opportunities. J Natl Compr Canc Netw. 6:515–522. 2008.PubMed/NCBI
|
|
25
|
Moens S, Goveia J, Stapor PC, Cantelmo AR
and Carmeliet P: The multifaceted activity of VEGF in angiogenesis
- Implications for therapy responses. Cytokine Growth Factor Rev.
25:473–482. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tabernero J: The role of VEGF and EGFR
inhibition: Implications for combining anti-VEGF and anti-EGFR
agents. Mol Cancer Res. 5:203–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chung YC, Hou YC, Chang CN and Hseu TH:
Expression and prognostic significance of angiopoietin in
colorectal carcinoma. J Surg Oncol. 94:631–638. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lieu C, Heymach J, Overman M, Tran H and
Kopetz S: Beyond VEGF: Inhibition of the fibroblast growth factor
pathway and antiangiogenesis. Clin Cancer Res. 17:6130–6139. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yancopoulos GD, Davis S, Gale NW, Rudge
JS, Wiegand SJ and Holash J: Vascular-specific growth factors and
blood vessel formation. Nature. 407:242–248. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dvorak HF: Discovery of vascular
permeability factor (VPF). Exp Cell Res. 312:522–526. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Folkman J: Angiogenesis: An organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
